Cancer Therapies - Global Market Opportunities

1.METHODOLOGY
Study Reliability and Reporting Limitations
Disclaimers
Quantitative Techniques & Reporting Level
2.GLOBAL MARKET OVERVIEW AND OUTLOOK
Cancer Therapies: A Prelude
Patent Expiries of Branded Drugs to Trigger Generic Competition
New Cancer Therapies Appear Over the Horizon
New Generation Cancer Drugs and Their Area of Use
The New Era of Cancer Treatment
Biotech Cancer Therapies Yet to Overcome Teething Issues
Targeted Therapy: The New Frontier of Cancer Treatment
Combination Therapy: A Double Whammy Success
Small Cap Companies: A Target of Private Capital Financing
Shifting Therapeutic Preferences
Innovations in Cancer Drug Delivery: A Key Factor in Product Differentiation
Personalized Medicine: Gain in Importance
Growth Drivers In a Capsule
Rise in Cancer Incidences & Access to Modern Therapeutics Foster Growth
Demographics & Lifestyles Raise the Risk of Cancer
Unmet Needs Leave Scope for Further Research and Development
Low Entry Barriers in Cancer Research Encourages Breakthrough Developments
Increasing Investments by National Health Authorities
Efficiency & High Prices Magnetize Manufacturers
Supportive Cancer Drugs Contribute to Growth
Improved Screening, Diagnosis & Patient Survival Rates Trigger Growth
Molecular Imaging of Cancer: Critical in Improving Patient Outcomes
Innovations, Improvements, and Approvals Propel Growth
Growth Restraints
High Prices of Targeted Therapies Act as a Speed Breaker
Limited Tumor Specificity and Toxicity
Complicated Treatment Protocols: A Major Stumbling Block in Patient Compliance
Reduced Smoking
Reimbursement and Coverage Remains a Major Challenge
Changes in Reimbursement Policies Influence Market Prospects
Multiple Drug Resistance
Stringent Regulations Delay Market Approval
Challenges Encountered in Clinical Trials
High Development Costs Retracts Manufacturers in Developing Countries
Notes From Across the Globe
United States
Medicare Restructures its Coverage for Chemotherapy
Personalized Care for Cancer Treatment in US
Drugs in Development in the US
Statistical Findings
Australia
Asia
India
Japan
Korea
Malaysia
Europe
Advancements in Breast Cancer Treatment in Europe
Latin America
Brazil
Mexico
Argentina
3.PRODUCT FACTS
Chemotherapy
Targeted Therapy
Hormonal Therapy
Immunotherapy
4.CORPORATE DEVELOPMENTS
Avexa to Acquire Progen Pharmaceuticals
ABRAXANE Gains Marketing Approval in Korea, Australia and Other Countries
GlaxoSmithKline's Cervarix Finds Place in UK National Immunization Programme
Biogen Idec and Elan Commence Clinical Trial of TYSABRI
GlaxoSmithKline Receives Conditional EU Approval for Marketing Lapatinib
Roche’s Xeloda Gains EU Approval for Use in Colorectal Cancer Treatment
Genentech Secures FDA Approval for Avastin
EU Approves Four Biosimilar Versions of Neupogen
Threshold Pharmaceuticals Starts Phase I/II Clinical Trials of TH-302
GSK’s Tykerb Receives USFDA Approval
Seattle Genetics Initiates Phase 1b Clinical Trials of SGN-40 with Gemzar and Rituxan
Merck Serono Initiates Phase III Trials of Cladribine
Imclone Awaits Approval for Erbitux from US Medicine Regulator
FDA Awards Orphan Drug Designation for the Use of Stem Cell Technology in Bone Marrow Transplantations
Roche, OSI and Chugai Receive Approval for Tarceva in Japan
Novartis’ Everolimus Awaits Approvals from US FDA, Swissmedic, and EMEA
Abraxis BioScience, AstraZeneca, and NCCN to Conduct Anti-cancer Drug Studies
Sanofi-Aventis Receives Japanese Approval for Taxotere® Injection
GSK Launches Cervarix in Singapore
Abraxis Takes Over Platco and Shimoda
Novartis Inks a Production Deal with Lonza
Roche to Take Over UK-Based Biotech Company, Piramed
Pfizer Acquires Encysive
FivePrime Join Hands with Pfizer for Cancer and Diabetes Research
Sanofi-Aventis and Dyax Ink Two Antibody Pacts
Pfizer and AVANT Ink a Global Licensing Agreement for CDX-110
Takeda Inks an Exclusive Partnership Agreement with Amgen
Genentech and Roche Ink a Licensing Agreement with Glycart
Bristol-Myers Squibb to Acquire Kosan Biosciences
Nabi Biopharmaceuticals Collaborates with NIAID
Pfizer to Acquire Serenex
GE Healthcare Inks a Three-Year Agreement with Eli Lilly
Abraxis Enters into Definitive License Agreements with ProMetic Life Sciences
Eli Lilly to Take Over ImClone Systems
Shanghai Roche Expands its MabThera Marketing Activities
GSK’s Hycamtin Obtains FDA Approval
Avastin Receives European Approval for Breast Cancer Treatment
Roche’s Tarceva Obtains European Approval
Roche’s NeoRecormon Gains European Approval
Merck Serono Receives EU Approval for mCRC Treatment With Erbitux
FDA Grants Approval for Sutent, a Kidney and Gastrointestinal Cancer Drug
Wyeth Pharmaceuticals’ TORISEL Receives FDA Approval
Merck Completes the Acquisition of Majority Stake in Serono
Merck Enters into Licensing and Collaboration Agreement With Idera
Sanofi-Aventis Inks a Global Licensing Deal with Oxford BioMedica
WEHI to Collaborate with Genentech and Roche
AstraZeneca Acquires MedImmune
Antisoma Enters into a Global Accord with Novartis
Sanofi-Aventis and Astellas Pharma to Restructure their JV Operations in Japan
Biomira Amends its Agreements with Merck
AstraZeneca Takes Over Canadian Biologics Plant
Pfizer to Acquire Coley Pharmaceutical Group
Abraxis Takes Over Watson’s Manufacturing Facility
Abraxis Takes Over Pfizer’s Cruce Davila Manufacturing Facility
Bristol-Myers Squibb to Take Over Adnexus Therapeutics
Merck to Partner with a Florida-based Research Center
Genzyme to Acquire Bioenvision
Genentech Inks a Deal with Seattle Genetics
Roche to Acquire CuraGen’s Subsidiary
5.MAJOR PLAYERS
Abraxis BioScience, Inc. (USA)
Amgen, Inc. (USA)
AstraZeneca PLC (UK)
Bayer Schering Pharma (Germany)
Biogen Idec Inc (USA)
Bristol-Myers Squibb Company (USA)
Celgene Corporation (USA)
Cell Therapeutics, Inc. (USA)
Cephalon, Inc. (USA)
Chugai Pharmaceutical Co., Ltd. (Japan)
Eli Lilly and Company (USA)
F. Hoffmann-La Roche Ltd (Switzerland)
Genentech, Inc. (USA)
Genzyme (USA)
GlaxoSmithKline (UK)
Imclone Systems, Inc (USA)
Merck KGaA (Germany)
Novartis AG (Switzerland)
Ortho Biotech Products, L.P (USA)
OSI Pharmaceuticals, Inc. (USA)
Pfizer (USA)
Sanofi-Aventis (France)
Schering Plough Corporation (USA)
Seattle Genetics, Inc. (USA)
Takeda Pharmaceutical Company Limited (Japan)
Wyeth (USA)
6.GLOBAL MARKET ANALYTICS
Table 1: Percentage Breakdown of Global Biotech-Enabled Cancer Therapies Market by Application –
Table 2: Percentage Breakdown of Molecular Targeted Therapies Under Pipeline by Drug Class in the World - As of
Table 3: Venture Capital Investment (In US$ Millions) Made in Research and Development of Biotechnology for the years 2004 and -
Table 4: Percentage Breakdown of Revenues in the Global Market for Antihormonal Therapy by Drug Class – 2014P
Table 5: Percentage Breakdown of Revenues in the US Market for Hospital Cancer Therapies by Treatment Type –
Table 6: Percentage Breakdown of Revenues in the US Market for Chemotherapy Drugs by Drug Class –
Table 7: Percentage Revenue Breakdown of Leading Players in the US Market for Multiple Myeloma
Table 8: Percentage Revenue Breakdown of Leading Players in the US Market for Cancer Therapies –
Table 9: Percentage Breakdown of Revenues in the US Market for Breast Cancer Therapeutics by Segment –
Table 10: Percentage Breakdown of Revenues in the European Market for Breast Cancer Therapeutics by Drug Class –
Table 11: Percentage Breakdown of Revenues in the Global Market for Immunotherapy by Drug Class - 2012P
Table 12: Global Market for Cancer Therapies by Type: 2007-2015 (Sales in US$ Billion)
Table 13: Percentage Breakdown of Global Cancer Therapies Market by Type for the Years 2009 &
Companies Profiled